This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Vitamin D analogues in the treatment of psoriasis

Authoring team

  • calcipotriol and tacalcitol are topical vitamin D analogues which inhibit keratinocyte proliferation and induce terminal differentiation
  • trials show calcipotriol to be as effective as dithranol
  • topical vitamin D analogues are often the first line treatment for psoriasis in primary care
  • topical vitamin D analogues can cause local irritation and excessive use can lead to hypercalcaemia (1) - has led to the use of combinations of vitamin D analogues with other topical therapies, UV phototherapy and systemic therapies
  • a systematic review found that in head-to-head comparisons of vitamin D against potent or very potent corticosteroids there were no significant differences. However, combined treatment with vitamin D /corticosteroid performed significantly better than either vitamin D alone or corticosteroid alone (1)

A suggested protocol for the use of topical preparations in psoriasis is presented in the linked item.

Reference:

  1. Prescriber (2005); 16 (8).
  2. Prescribers' Journal (1993);33(5): 183-91.
  3. Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis.Cochrane Database Syst Rev. 2009 Apr 15;(2):CD005028.

 


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.